Notice of Results
Tissue Regenix Group plc
('Tissue Regenix', the 'Group', or the 'Company')
Notice of full year results
Investor presentation
Tissue Regenix Group plc (AIM: TRX), the regenerative medical devices company, will announce its final results for the year ended 31 December 2023 on Tuesday 19 March 2024.
Investor Briefing
Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer, will host a live online presentation relating to the final results via the Investor Meet Company platform at 11.00am on Tuesday 19 March 2024. The presentation is open to all existing and potential shareholders.
Investors can sign up to Investor Meet Company for free and register for the presentation here:
https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor
Investors who already follow Tissue Regenix on the Investor Meet Company platform will be de facto invited.
For more information:
|
Tissue Regenix Group plc |
||
|
David Cocke, Chief Financial Officer |
via Walbrook PR |
|
|
|
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and Broker) |
|
|
|
Emily Watts/Geoff Nash/George Dollemore - Corporate Finance |
|
|
|
Nigel Birks/Harriet Ward - ECM |
|
|
|
|
|
|
|
Walbrook PR (Financial PR and IR) |
Tel: +44 (0)20 7933 8780 |
|
|
Alice Woodings/Charlotte Edgar |
TissueRegenix@walbrookpr.com |
|
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.
In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 8 hours ago Urban Logistics Reit
- 8 hours ago Ocado Group
- 8 hours ago AJ Bell
- 8 hours ago Foresight Enterprise VCT
- 8 hours ago Mitie Group